Does obesity affect long-term outcomes of extreme lateral interbody fusion with posterior stabilization?

Extreme lateral interbody fusion Functional outcomes Graft subsidence Lateral lumbar interbody fusion Lumbar fusion Obese Obesity Outcomes Revision

Journal

The spine journal : official journal of the North American Spine Society
ISSN: 1878-1632
Titre abrégé: Spine J
Pays: United States
ID NLM: 101130732

Informations de publication

Date de publication:
08 2021
Historique:
received: 23 11 2020
revised: 24 02 2021
accepted: 08 03 2021
pubmed: 22 3 2021
medline: 28 10 2021
entrez: 21 3 2021
Statut: ppublish

Résumé

Obese patients can pose significant challenges to spine surgeons in lumbar fusion procedures. The increased risk of complications has led surgeons to be wary in pursing operative interventions in these patients. Since the advent of minimally-invasive techniques in lumbar fusion, surgeons are turning to these procedures in an attempt to minimize operative time, blood loss and overall cost. With an increased proportion of obese patients in the population, it is imperative to understand the long-term outcomes in these minimally-invasive approaches. The purpose of this study was to evaluate the long-term safety and efficacy of extreme lateral interbody fusion (XLIF) in the obese. Retrospective cohort study. A total of 115 patients (53 nonobese and 62 obese) who underwent XLIF with a minimum of 5-year follow-up. (1) Patient reported outcome scores: Visual Analog Scale (VAS) for back pain, Oswestry Disability Index (ODI), (2) Reoperation rate, (3) Pelvic incidence (PI)- Lumbar lordosis (LL) mismatch correction, (4) Graft subsidence and fusion rate METHODS: A retrospective review was performed to identify patients who underwent XLIF with percutaneous posterior stabilization since 2007 with a minimum follow-up of 5 years. Demographics including BMI were recorded and patients were subdivided into 2 cohorts: nonobese (BMI <30 kg/m A total of 115 consecutive patients were included (53 nonobese and 62 obese) with a mean follow up of 95.3 months. Mean BMI was 25.3 in the nonobese group and 35.3 in the obese group (p<.001). There were more females in nonobese cohort. VAS scores decreased by a mean of 5.7 in the nonobese cohort, and 5.4 in the obese cohort (p=.213). ODI improvement was also similar between the groups. 5.6% of nonobese patients required reoperation compared to 9.6% of obese patients (p=.503). Graft subsidence rates at final follow-up were 5.66% and 8.06% for the nonobese and obese groups, respectively (p=.613). Rates of successful fusion were 96.23% and 98.39% for the nonobese and obese groups, respectively (p=.469). Both cohorts achieved a similar proportion of PI-LL mismatch correction, 85% in obese versus 78% in nonobese patients (p=.526). Obese patients have similar surgical outcomes to nonobese patients with respect to functional outcome scores, reoperation rates, graft subsidence and correction of PI-LL mismatch after long-term follow-up. With similar outcome and reoperation profiles, minimally-invasive approaches to the spine, such as XLIF, may be an acceptable alternative to traditional open procedures in obese patients.

Sections du résumé

BACKGROUND CONTEXT
Obese patients can pose significant challenges to spine surgeons in lumbar fusion procedures. The increased risk of complications has led surgeons to be wary in pursing operative interventions in these patients. Since the advent of minimally-invasive techniques in lumbar fusion, surgeons are turning to these procedures in an attempt to minimize operative time, blood loss and overall cost. With an increased proportion of obese patients in the population, it is imperative to understand the long-term outcomes in these minimally-invasive approaches.
PURPOSE
The purpose of this study was to evaluate the long-term safety and efficacy of extreme lateral interbody fusion (XLIF) in the obese.
STUDY DESIGN/SETTING
Retrospective cohort study.
PATIENT SAMPLE
A total of 115 patients (53 nonobese and 62 obese) who underwent XLIF with a minimum of 5-year follow-up.
OUTCOME MEASURES
(1) Patient reported outcome scores: Visual Analog Scale (VAS) for back pain, Oswestry Disability Index (ODI), (2) Reoperation rate, (3) Pelvic incidence (PI)- Lumbar lordosis (LL) mismatch correction, (4) Graft subsidence and fusion rate METHODS: A retrospective review was performed to identify patients who underwent XLIF with percutaneous posterior stabilization since 2007 with a minimum follow-up of 5 years. Demographics including BMI were recorded and patients were subdivided into 2 cohorts: nonobese (BMI <30 kg/m
RESULTS
A total of 115 consecutive patients were included (53 nonobese and 62 obese) with a mean follow up of 95.3 months. Mean BMI was 25.3 in the nonobese group and 35.3 in the obese group (p<.001). There were more females in nonobese cohort. VAS scores decreased by a mean of 5.7 in the nonobese cohort, and 5.4 in the obese cohort (p=.213). ODI improvement was also similar between the groups. 5.6% of nonobese patients required reoperation compared to 9.6% of obese patients (p=.503). Graft subsidence rates at final follow-up were 5.66% and 8.06% for the nonobese and obese groups, respectively (p=.613). Rates of successful fusion were 96.23% and 98.39% for the nonobese and obese groups, respectively (p=.469). Both cohorts achieved a similar proportion of PI-LL mismatch correction, 85% in obese versus 78% in nonobese patients (p=.526).
CONCLUSION
Obese patients have similar surgical outcomes to nonobese patients with respect to functional outcome scores, reoperation rates, graft subsidence and correction of PI-LL mismatch after long-term follow-up. With similar outcome and reoperation profiles, minimally-invasive approaches to the spine, such as XLIF, may be an acceptable alternative to traditional open procedures in obese patients.

Identifiants

pubmed: 33744435
pii: S1529-9430(21)00121-2
doi: 10.1016/j.spinee.2021.03.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1318-1324

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Stuart Changoor (S)

St. Joseph's University Medical Center, Department of Orthopaedic Surgery, 703 Main Street, Paterson, NJ 07503, USA.

Conor Dunn (C)

St. Joseph's University Medical Center, Department of Orthopaedic Surgery, 703 Main Street, Paterson, NJ 07503, USA.

Daniel Coban (D)

St. Joseph's University Medical Center, Department of Orthopaedic Surgery, 703 Main Street, Paterson, NJ 07503, USA.

Aksha Parray (A)

Rutgers New Jersey Medical School, 185 South Orange Ave, Newark, NJ 07103, USA.

Kumar Sinha (K)

St. Joseph's University Medical Center, Department of Orthopaedic Surgery, 703 Main Street, Paterson, NJ 07503, USA.

Ki Soo Hwang (KS)

St. Joseph's University Medical Center, Department of Orthopaedic Surgery, 703 Main Street, Paterson, NJ 07503, USA.

Michael Faloon (M)

St. Joseph's University Medical Center, Department of Orthopaedic Surgery, 703 Main Street, Paterson, NJ 07503, USA.

Arash Emami (A)

St. Joseph's University Medical Center, Department of Orthopaedic Surgery, 703 Main Street, Paterson, NJ 07503, USA. Electronic address: emamiresearch@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH